To include your compound in the COVID-19 Resource Center, submit it here.

KemPharm hammered after FDA panel

KemPharm Inc. (NASDAQ:KMPH) sank $8.76 (56%)

Read the full 67 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE